Covista Inc

Análisis de la acción Covista Inc (CVSA)

$131.820

+0.198 (+0.15%)Al cierre

Loading chart…
Máximo
132.580
Apertura
131.230
Precio medio ponderado por volumen
131.71
Volumen
250.02K
Capitalización
—
Mínimo
130.735
Importe
32.93M
EV/EBITDA, TTM
9.38

Covista Inc., formerly Adtalem Global Education Inc., is a healthcare educator serving across five accredited institutions. Its institutions include American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. It provides personalized, tech-enabled access to healthcare careers. Its American University of the Caribbean School of Medicine provides medical education with a focus on clinical experience across its two campuses in Sint Maarten and Preston, United Kingdom. Chamberlain University is an educator for nursing students in the United States, offering nursing and healthcare programs at over 24 campuses nationwide and online. Walden University provides healthcare education for working professionals through a range of online programs which include nursing, health sciences, public health and healthcare leadership.

www.covista.com

Análisis de IA of Covista Inc (CVSA)

Mantener

Covista Inc is currently a hold. The stock is priced at $126.75, which is below the average analyst price target of $145, indicating potential upside. However, the RSI is at 44.605, suggesting the stock is nearing oversold territory but not yet a strong buy signal. The forward P/E ratio of 13.6054 is attractive, indicating reasonable valuation, but recent insider selling raises caution. The main risk is the recent insider sales, with the CEO selling shares worth approximately $690,000, which could signal caution among executives.

Métricas de valoración

El PER previsto actual de Covista Inc (CVSA) es 13.61, frente a su media de 5 años de 14.36.

PER previsto

Valor razonable
Media 5A P/E
14.36
P/E actual
13.61
Sobrevalorada
15.70
Infravalorada
13.01

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
9.46
EV/EBITDA actual
9.38
Sobrevalorada
10.18
Infravalorada
8.75

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.98
P/S actual
1.93
Sobrevalorada
2.10
Infravalorada
1.86

Ballenas con CVSA en cartera

Ö

ÖKoworld Lux S.A.

+ Con en carteraCVSA

+1.66%

Rentabilidad a 3 meses

A

Ariel Investments, LLC

+ Con en carteraCVSA

-4.55%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-15 (ET)

09:30:00

Covista Invests $150,000 in THC to Expand Healthcare Career Exploration

2026-09-14 (ET)

08:30:00

Chamberlain University Appoints Jason Dunne as Chief Academic Officer

2026-08-06 (ET)

17:30:00

Covista Q4 Revenue of $501.4M Exceeds Expectations

17:30:00

Sees FY27 Revenue at $2.05B-$2.09B

2026-07-28 (ET)

08:30:00

Covista Appoints Emily Chiu and Leslie Storms to Board of Directors

Noticias

Preguntas frecuentes sobre CVSA, respondidas por Alphio AI

Covista Inc., formerly Adtalem Global Education Inc., is a healthcare educator serving across five accredited institutions. Its institutions include American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. It provides personalized, tech-enabled access to healthcare careers. Its American University of the Caribbean School of Medicine provides medical education with a focus on clinical experience across its two campuses in Sint Maarten and Preston, United Kingdom. Chamberlain University is an educator for nursing students in the United States, offering nursing and healthcare programs at over 24 campuses nationwide and online. Walden University provides healthcare education for working professionals through a range of online programs which include nursing, health sciences, public health and healthcare leadership. It operates in the Academic & Educational Services sector.

Covista Inc is currently a hold. The stock is priced at $126.75, which is below the average analyst price target of $145, indicating potential upside. However, the RSI is at 44.605, suggesting the stock is nearing oversold territory but not yet a strong buy signal. The forward P/E ratio of 13.6054 is attractive, indicating reasonable valuation, but recent insider selling raises caution. The main risk is the recent insider sales, with the CEO selling shares worth approximately $690,000, which could signal caution among executives.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar